CARE PAH study design: an international, prospective real-world cohort of PAH patients
M. Humbert (Paris, France), N. Dreyer (Cambridge, United States), V. Mclaughlin (Ann Arbor, United States), T. Pulido (Mexico City, Mexico), N. Boyanova (Allschwil, Switzerland), B. Frauchiger (Allschwil, Switzerland), F. Kiefer (Allschwil, Switzerland), C. Lassen (Allschwil, Switzerland), R. Ong (Allschwil, Switzerland), L. Sanna (Allschwil, Switzerland), A. Sauter (Allschwil, Switzerland), D. Kiely (Sheffield, United Kingdom)
Source: International Congress 2022 – Treatment of pulmonary arterial hypertension
Session: Treatment of pulmonary arterial hypertension
Session type: Thematic Poster
Number: 2676
 
Rating: 
You must login to grade this presentation.
Share or cite this content
Citations should be made in the following way:
M. Humbert (Paris, France), N. Dreyer (Cambridge, United States), V. Mclaughlin (Ann Arbor, United States), T. Pulido (Mexico City, Mexico), N. Boyanova (Allschwil, Switzerland), B. Frauchiger (Allschwil, Switzerland), F. Kiefer (Allschwil, Switzerland), C. Lassen (Allschwil, Switzerland), R. Ong (Allschwil, Switzerland), L. Sanna (Allschwil, Switzerland), A. Sauter (Allschwil, Switzerland), D. Kiely (Sheffield, United Kingdom). CARE PAH study design: an international, prospective real-world cohort of PAH patients. 2676
You must login to share this Presentation/Article on Twitter, Facebook, LinkedIn or by email.
Member's Comments
Related content which might interest you:
|
|